Subcutaneous Implantable Naltrexone Pellets – Commercial Medical Benefit Drug Policyopen_in_new

UnitedHealthcare considers compounded subcutaneous implantable naltrexone pellets not FDA‑approved and not medically necessary (experimental/unproven) and limits their use to clinical trials. This policy excludes the FDA‑approved Vivitrol® (J2315), and actual coverage depends on the member‑specific benefit plan and applicable federal/state mandates.

"No specific clinical documentation requirements (e."

Sign up to see full coverage criteria, indications, and limitations.